Obstructive Sleep Apnea Clinical Trial Pipeline Expands As 12+ Companies Driving Innovation In OSA Therapeutics Delveinsight

(MENAFN- GlobeNewsWire - Nasdaq) The obstructive sleep apnea (OSA) market is being propelled by the rapid evolution of early detection and diagnostic tools. Technologies like home sleep apnea testing (HSAT), AI-powered applications, and smart wearables are transforming the diagnostic landscape by making it more accessible and user-friendly. These innovations not only reduce the dependency on traditional sleep labs but also facilitate earlier diagnosis and timely intervention. As a result, more patients are entering the treatment pathway, supporting both improved clinical outcomes and sustained market expansion.

New York, USA, July 16, 2025 (GLOBE NEWSWIRE) -- Obstructive Sleep Apnea Clinical Trial Pipeline Expands as 12+ Companies Driving Innovation in OSA Therapeutics | DelveInsight

The obstructive sleep apnea (OSA) market is being propelled by the rapid evolution of early detection and diagnostic tools. Technologies like home sleep apnea testing (HSAT), AI-powered applications, and smart wearables are transforming the diagnostic landscape by making it more accessible and user-friendly. These innovations not only reduce the dependency on traditional sleep labs but also facilitate earlier diagnosis and timely intervention. As a result, more patients are entering the treatment pathway, supporting both improved clinical outcomes and sustained market expansion.

DelveInsight's ' Obstructive Sleep Apnea Pipeline Insight 2025 ' report provides comprehensive global coverage of pipeline obstructive sleep apnea therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the obstructive sleep apnea pipeline domain.

Key Takeaways from the Obstructive Sleep Apnea Pipeline Report

• DelveInsight's obstructive sleep apnea pipeline report depicts a robust space with 12+ active players working to develop 14+ pipeline obstructive sleep apnea drugs.
• Key obstructive sleep apnea companies such as Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, KYORIN Pharmaceutical Co., Shionogi Apnimed Sleep Science , and others are evaluating new obstructive sleep apnea drugs to improve the treatment landscape.
• Promising pipeline obstructive sleep apnea therapies, such as Sulthiame, IHL-42X, Lorundrostat, Retatrutide, BAY2925976, SASS-001, and others, are in different phases of obstructive sleep apnea clinical trials.
• In June 2025 , Innovent Biologics, Inc. announced that the first participant had been successfully dosed in a Phase III clinical trial (GLORY-OSA) of Mazdutide , a dual glucagon (GCG) and glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese participants with moderate-to-severe obstructive sleep apnea (OSA) and obesity (BMI ≥ 28 kg/m2).
• In April 202 5, Apnimed announced that the first patient had been dosed in the Phase IIA RESTEADY trial evaluating the novel oral drug combination, SASS-001 , in an underserved population of patients suffering from sleep apnea with a central component. Top-line results from the study are expected in the first half of 2026. SASS-001 represents the first clinical stage asset from Shionogi-Apnimed Sleep Science, LLC (SASS), Apnimed's joint venture with Shionogi & Co., Ltd. (Shionogi).
• In April 2025 , Shionogi & Co., Ltd. announced that it had entered into an agreement with Apnimed, Inc. for the introduction of sulthiame * and a new drug development program. With the conclusion of this agreement, Shionogi acquired a joint ownership interest in the intellectual property rights related to the use of sulthiame in the field of sleep apnea and also in other intellectual property rights related to a different drug development program of Apnimed by paying a one-time fee to Apnimed.
• In April 2025 , Apnimed announced that it had acquired the intellectual property and exclusive global rights to develop and commercialize sulthiame , a differentiated carbonic anhydrase inhibitor, in the broad field of sleep apnea and sleep-related breathing diseases, from D esitin Arzneimittel GmbH . Apnimed will develop sulthiame with Shionogi & Co. Ltd. through their joint venture, Shionogi-Apnimed Sleep Science (SASS).
• In April 2025 , Incannex Healthcare Inc. announced that the Company has completed Phase II patient enrollment in the global Phase II/III RePOSA study of IHL-42X for the treatment of Obstructive Sleep Apnea (OSA). IHL-42X is an oral fixed dose combination medicine designed to reduce the incidence of interruptions to breathing during sleep and improve sleep quality.
• In January 2025 , Mineralys Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) had cleared the Company's Investigational New Drug (IND) Application for a Phase II clinical trial to evaluate the effect of lorundrostat in the treatment of subjects with moderate-to-severe obstructive sleep apnea (OSA) and hypertension.

Request a sample and discover the recent advances in obstructive sleep apnea drugs @ Obstructive Sleep Apnea Pipeline Report

The obstructive sleep apnea pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Obstructive Sleep Apnea drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the obstructive sleep apnea clinical trial landscape.

Obstructive Sleep Apnea Overview

Obstructive sleep apnea (OSA) is a sleep disorder marked by repeated episodes of partial or complete blockage of the upper airway during sleep. These episodes cause drops in oxygen levels and frequent awakenings, resulting in fragmented, poor-quality sleep. Common signs include loud snoring, witnessed pauses in breathing, and excessive daytime sleepiness. OSA can have wide-ranging health effects, impairing cardiovascular health, behavior, quality of life, and even driving safety. While other types of sleep-disordered breathing, such as central sleep apnea, upper airway resistance syndrome, and obesity hypoventilation, share some features with OSA, they are distinct conditions and will be discussed separately.

The symptoms of OSA vary and can severely impact day-to-day functioning. These include persistent daytime drowsiness, loud snoring, gasping or choking during sleep, morning headaches, dry mouth or sore throat upon waking, difficulty concentrating, mood disturbances such as irritability or depression, high blood pressure, and reduced libido. These manifestations can greatly affect both physical well-being and overall life quality.

The underlying cause of OSA involves upper airway obstruction during sleep, mainly due to negative pressure that causes the airway to collapse during inhalation. A key area of concern is the narrowing of the airway in the retropalatal region during exhalation. Obesity is a significant risk factor, with a higher body mass index (BMI) linked to greater airway narrowing. Both structural factors (like airway size) and neuromuscular control contribute to this condition. Understanding how airflow interacts with pressure in collapsible airways is vital to grasping the mechanics of OSA. Additional anatomical and physiological factors also influence the severity of the disorder.

Managing OSA requires a personalized and multifaceted approach. For mild-to-moderate cases, lifestyle changes, such as losing weight, maintaining good sleep habits, and avoiding alcohol and sedatives, are important first steps. Continuous positive airway pressure (CPAP) therapy is the most effective treatment for moderate-to-severe OSA, though adherence can be difficult. Alternatives like oral appliances, especially mandibular advancement devices, may help in less severe cases. Surgical options, including uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement (MMA), and hypoglossal nerve stimulation (HNS), may be considered for more severe or treatment-resistant cases. In rare, severe situations, a tracheostomy may be necessary, particularly for patients with significant comorbidities. Ultimately, the best outcomes are achieved through an individualized treatment plan that may combine several strategies to relieve symptoms, improve sleep quality, and enhance overall health.

Find out more about obstructive sleep apnea drugs @ Obstructive Sleep Apnea Treatment

A snapshot of the Pipeline Obstructive Sleep Apnea Drugs mentioned in the report:

Drugs	Company	Phase	MoA	RoA
AD109	Apnimed	III	Adrenergic uptake inhibitors; Cholinergic receptor antagonists; Muscarinic receptor antagonists	Oral
Retatrutide	Eli Lilly and Company	III	Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists	Subcutaneous
IHL-42X	Incannex Healthcare Ltd	II/III	Cannabinoid receptor CB2 agonists; Carbonic anhydrase inhibitors	Oral
Lorundrostat	Mineralys Therapeutics Inc.	II	Aldosterone synthase inhibitors	Oral
Sulthiame	Apnimed	II	Carbonic anhydrase inhibitors	Oral
SASS-001	Shionogi Apnimed Sleep Science	II	Purinergic P2X3 receptor antagonists	Oral

Learn more about the emerging obstructive sleep apnea therapies @ Obstructive Sleep Apnea Clinical Trials

Obstructive Sleep Apnea Therapeutics Assessment

The obstructive sleep apnea pipeline report proffers an integral view of the emerging obstructive sleep apnea therapies segmented by stage, product type, molecule type, route of administration, and mechanism of action.

Scope of the Obstructive Sleep Apnea Pipeline Report

• Coverage : Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type : Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Therapeutics Assessment By Mechanism of Action : Adrenergic uptake inhibitors, Cholinergic receptor antagonists, Muscarinic receptor antagonists, Cannabinoid receptor CB2 agonists, Carbonic anhydrase inhibitors, Aldosterone synthase inhibitors, Glucagon-like peptide-1 receptor agonists, Purinergic P2X3 receptor antagonists
• Key Obstructive Sleep Apnea Companies : Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, KYORIN Pharmaceutical Co., Shionogi Apnimed Sleep Science, and others.
• Key Obstructive Sleep Apnea Pipeline Therapies : Sulthiame, IHL-42X, Lorundrostat, Retatrutide, BAY2925976, SASS-001, and others.

Dive deep into rich insights for new obstructive sleep apnea treatments, visit @ Obstructive Sleep Apnea Drugs

Table of Contents

1.	Obstructive Sleep Apnea Pipeline Report Introduction
2.	Obstructive Sleep Apnea Pipeline Report Executive Summary
3.	Obstructive Sleep Apnea Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Obstructive Sleep Apnea Clinical Trial Therapeutics
6.	Obstructive Sleep Apnea Pipeline: Late-Stage Products (Pre-registration)
7.	Obstructive Sleep Apnea Pipeline: Late-Stage Products (Phase III)
8.	Obstructive Sleep Apnea Pipeline: Mid-Stage Products (Phase II)
9.	Obstructive Sleep Apnea Pipeline: Early-Stage Products (Phase I)
10.	Obstructive Sleep Apnea Pipeline Therapeutics Assessment
11.	Inactive Products in the Obstructive Sleep Apnea Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the Obstructive Sleep Apnea Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the obstructive sleep apnea pipeline therapeutics, reach out @ Obstructive Sleep Apnea Therapeutics

Related Reports

Obstructive Sleep Apnea Epidemiology Forecast

Obstructive Sleep Apnea Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted obstructive sleep apnea epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Obstructive Sleep Apnea Market

Obstructive Sleep Apnea Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key obstructive sleep apnea companies, including Apnimed, Eli Lilly and Company, Nyxoah Inc., ICUREsearch, Eisai Inc., Purdue Pharma LP, Desitin Arzneimittel GmbH, Berendo Scientific LLC, Sumitomo Pharma America Inc., Apnex Medical Inc., among others.

Sleep Apnea Market

Sleep Apnea Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key sleep apnea companies, including Apnimed, Incannex Healthcare, Fujian Shengdi Pharmaceutical, Eli Lilly and Company, RespireRx Pharmaceuticals, Neurim Pharmaceuticals, among others.

Sleep Apnea Pipeline

Sleep Apnea Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key sleep apnea companies, including Apnimed, Incannex Healthcare, Fujian Shengdi Pharmaceutical, Eli Lilly and Company, RespireRx Pharmaceuticals, Neurim Pharmaceuticals, among others.

Sleep Apnea Diagnostic Devices Market

Sleep Apnea Diagnostic Devices Market Insights, Competitive Landscape and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key sleep apnea diagnostic devices companies, including Natus Medical Incorporated., SOMNOmedics GmbH, Compumedics Limited, ZOLL Itamar Ltd., Nihon Kohden Corporation, Vyaire., Cleveland Medical Devices Inc., Cadwell Industries Inc., Koninklijke Philips N.V., InMode Aesthetic Solutions, ResMed, Resonea, DeVilbiss Healthcare LLC, Smiths Group Plc. (Smiths Medical), Hemodiaz Life Sciences Private Limited., ActiGraph, LLC., Advin Health Care, Recorders & Medicare Systems Pvt Ltd (RMS), Allengers, EB Neuro S.p.A. , among others.

DelveInsight's Pharma Competitive Intelligence Service : Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.

Other Business Pharmaceutical Consulting Services

Healthcare Conference Coverage

Pipeline Assessment

Healthcare Licensing Services

Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

Connect with us at LinkedIn

CONTACT: Contact Us Shruti Thakur ... +14699457679

MENAFN16072025004107003653ID1109809681